PLYX

Polaryx Therapeutics is a clinical-stage biotech company developing treatments for rare, pediatric lysosomal storage diseases (LSDs) using small molecules and gene therapy to address the underlying causes of these diseases. The lead candidate, PLX-200, is an oral small molecule being advanced through a Phase 2 basket trial expected to launch in late 2026 across four LSDs including CLN2, CLN3, Krabbe disease, and Sandhoff disease. PLX-200 is a reformulated version of an existing drug being pursued through an expedited regulatory pathway, with potential eligibility for accelerated FDA approval based on precedent in similar LSDs.

Pipeline

Catalyst Calendar